DXCM - 2 Monster Stocks to Buy Without Any Hesitation
2023-04-25 10:20:00 ET
Eli Lilly (NYSE: LLY) and DexCom (NASDAQ: DXCM) have characteristics in common that, in my view, make them monster stocks to buy without hesitation. Over the past five years, each healthcare company has shown strong growth in revenue and earnings per share (EPS). Not coincidentally, both companies' shares are up this year, and up by triple-digit percentages over the past five years.
Both companies also have major tailwinds that should help drive revenue for years. For Lilly, it's the potential in weight-loss drug Mounjaro and Alzheimer's therapy donanemab. For DexCom, profits will be driven by the trend toward greater numbers of diabetes patients and their need for continuous glucose monitoring devices (CGMs).
Eli Lilly has grown steadily, but it has a handful of therapies in the works that could supercharge the company's earnings. Over the past five years, Lilly has seen annual EPS climb by nearly 33% while annual revenue jumped by over 120%. So far this year, Lilly's shares are up a little more than 5%, but over the past five years, they're up by 387%.
For further details see:
2 Monster Stocks to Buy Without Any Hesitation